- Home
- LASR vs CGEM Comparison
LASR vs CGEM Comparison
Compare LASR & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LASR
- CGEM
- Stock Information
- Founded
- LASR 2000
- CGEM 2016
- Country
- LASR United States
- CGEM United States
- Employees
- LASR N/A
- CGEM N/A
- Industry
- LASR Semiconductors
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- LASR Technology
- CGEM Health Care
- Exchange
- LASR Nasdaq
- CGEM Nasdaq
- Market Cap
- LASR N/A
- CGEM 490.3M
- IPO Year
- LASR 2018
- CGEM 2021
- Fundamental
- Price
- LASR $8.61
- CGEM $7.77
- Analyst Decision
- LASR Strong Buy
- CGEM Strong Buy
- Analyst Count
- LASR 4
- CGEM 4
- Target Price
- LASR $15.13
- CGEM $33.50
- AVG Volume (30 Days)
- LASR 268.3K
- CGEM 458.7K
- Earning Date
- LASR 05-08-2025
- CGEM 05-08-2025
- Dividend Yield
- LASR N/A
- CGEM N/A
- EPS Growth
- LASR N/A
- CGEM N/A
- EPS
- LASR N/A
- CGEM N/A
- Revenue
- LASR $198,548,000.00
- CGEM N/A
- Revenue This Year
- LASR $8.26
- CGEM N/A
- Revenue Next Year
- LASR $10.40
- CGEM N/A
- P/E Ratio
- LASR N/A
- CGEM N/A
- Revenue Growth
- LASR N/A
- CGEM N/A
- 52 Week Low
- LASR $6.20
- CGEM $6.85
- 52 Week High
- LASR $14.73
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- LASR 60.32
- CGEM 44.72
- Support Level
- LASR $7.88
- CGEM $7.70
- Resistance Level
- LASR $8.60
- CGEM $8.97
- Average True Range (ATR)
- LASR 0.33
- CGEM 0.49
- MACD
- LASR 0.16
- CGEM -0.01
- Stochastic Oscillator
- LASR 97.38
- CGEM 18.37
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.